A small study found that it is feasible to detect BRCA1/2 reversion mutations in circulating cell-free DNA in patients with recurrent high-grade serous ovarian cancer. Those reversion mutations can help predict poor response to therapy in these patients.
Woman who undergo bilateral removal of ovaries at the time of hysterectomy have higher risks of all-cause mortality afterward, including hospital admission for ischemic heart disease.
An analysis of Lynch syndrome–associated ovarian cancer found that the malignancy tends to present at an early stage and has a generally good prognosis.
Women with endometrioid ovarian cancer present at a younger age and with earlier stage disease than those with serous ovarian cancer, according to a new analysis. The earlier presentation resulted in better 5- and 10-year overall survival rates as well.
The FDA granted accelerated approval to rucaparib (Rubraca), a PARP inhibitor, for the treatment of women with deleterious BRCA mutation-associated ovarian cancer.
A retrospective review showed that primary cytoreductive surgery was associated with longer survival than neoadjuvant chemotherapy in women with advanced-stage epithelial ovarian cancer.
Expression of mesothelium vascular cell adhesion molecule-1 (VCAM-1) is associated with poorer overall and progression-free survival in patients with epithelial ovarian cancer, according to a retrospective analysis.
The use of surveillance did not affect survival among women with stage I malignant ovarian germ cell tumors, according to a new retrospective analysis.
Adding the WEE1 inhibitor AZD1775 to carboplatin offered enhanced response rates in women with TP53-mutated ovarian cancer that was refractory or resistant to first-line platinum-based therapy in a phase II study.
Adding seribantumab to paclitaxel failed to improved progression-free survival in unselected patients with platinum-resistant or -refractory ovarian cancer. Expression of heregulin and HER2, however, could identify a subset of patients that derive benefit from the therapy.